Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.
about
Activities and Effects of Ergot Alkaloids on Livestock Physiology and ProductionIntegrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.Depression in patients with irritable bowel syndrome in Jos, NigeriaCurrent insights in to the pathophysiology of Irritable Bowel Syndrome.Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls.Role of serotonin in the pathophysiology of the irritable bowel syndrome.Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study.Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromeEfficacy and tolerability of levosulipride, domperidone and metoclopramide in patients with non-ulcer functional dyspepsia: a comparative analysis.Glucose-dependent trafficking of 5-HT3 receptors in rat gastrointestinal vagal afferent neurons.Effects of ramosetron on gastrointestinal transit of Guinea pig5-Fluorotryptamine is a partial agonist at 5-HT3 receptors, and reveals that size and electronegativity at the 5 position of tryptamine are critical for efficient receptor function.Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patientsLack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers.
P2860
Q26801490-B0486BC9-4D15-4448-831B-098FE22A4997Q33420644-6936D548-268F-4276-8F57-65B7B7AF7D79Q33724343-C0528213-B410-47B8-BA2F-208163DA0A18Q33866737-1BCFD0C8-8BE5-4F46-9633-DBA5196C3862Q33875272-8FE7E3C4-1805-4E47-8107-2E896FBB6123Q34552619-D64879BD-3A7A-41A1-A21E-DEB4F7657247Q35047066-A34ADE30-225B-4C3E-9E9D-597E274C84AAQ35128499-648B9BD0-D45D-44C1-B029-CF2A8356CFA4Q35362266-D69A31B7-E2D5-4AFF-B63C-DCCEEE9E6BE1Q35622698-A36FDF2D-7B92-4175-92DA-C29020BF03B7Q36230130-0046D314-E8F8-4C5B-A5D1-4DE2B114D2D9Q36542674-63710CA7-9078-41A2-AA20-D25280908925Q37112932-CEEB3958-2C38-407E-9D0C-95D3D18B96A4Q37636847-80343691-E94B-4339-89F6-CE8EAE355D08Q43201982-EAA77819-7C53-4E2F-B559-8E0E5764F23D
P2860
Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@ast
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@en
type
label
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@ast
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@en
prefLabel
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@ast
Review article: 5-hydroxytrypt ...... sation: clinical implications.
@en
P1476
Review article: 5-hydroxytrypt ...... nsation: clinical implications
@en
P2093
N J Talley
P304
P356
10.1111/J.1365-2036.1992.TB00050.X
P407
P577
1992-06-01T00:00:00Z